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Abstract
Background: Obesity is associated with macrophage infiltration of adipose tissue. These inflammatory cells affect
adipocytes not only by classical cytokines but also by the secreted glycopeptide wnt5a. Healthy adipocytes are able to
release the wnt5a inhibitor sFRP5. This protective effect, however, was found to be diminished in obesity. The aim of the
present study was to examine (1) whether obese human subjects exhibit increased serum concentrations of wnt5a and (2)
whether wnt5a and/or sFRP5 serum concentrations in obese subjects can be influenced by caloric restriction.
Methodology: 23 obese human subjects (BMI 44.161.1 kg/m
2) and 12 age- and sex-matched lean controls (BMI
22.360.4 kg/m
2) were included in the study. Obese subjects were treated with a very low-calorie diet (approximately
800 kcal/d) for 12 weeks. Body composition was assessed by impedance analysis, insulin sensitivity was estimated by
HOMA-IR and the leptin-to-adiponectin ratio and wnt5a and sFRP5 serum concentrations were measured by ELISA. sFRP5
expression in human adipose tissue biopsies was further determined on protein level by immunohistology.
Principal Findings: Pro-inflammatory wnt5a was not measurable in any serum sample of lean control subjects. In patients
with obesity, however, wnt5a became significantly detectable consistent with low grade inflammation in such subjects.
Caloric restriction resulted in a weight loss from 131.964.0 to 112.363.2 kg in the obese patients group. This was
accompanied by a significant decrease of HOMA-IR and leptin-to-adiponectin ratio, indicating improved insulin sensitivity.
Interestingly, these metabolic improvements were associated with a significant increase in serum concentrations of the anti-
inflammatory factor and wnt5a-inhibitor sFRP5.
Conclusions/Significance:Obesityisassociatedwithelevatedserumlevelsofpro-inflammatorywnt5ainhumans.Furthermore,
caloric restriction beneficially affects serum concentrations of anti-inflammatory sFRP5 in such subjects. These findings suggest
a novel regulatory system in low grade inflammation in obesity, which can be influenced by nutritional therapy.
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Introduction
During the last decades the mean body mass index (BMI) is
increasing continuously in most countries within the western world
making obesity one of the most important health problems.
Especially in patients with co-morbidities, such as hypertension
and type 2 diabetes, low grade inflammation has been observed in
the absence of infections or classical immunological diseases [1].
Several recent reports in cell lines [2], animal models [3] and
humans [4,5] suggest that these inflammatory reactions are not
only associated with obesity but are causally involved in the
pathogenesis of obesity and its co-morbidities.
Macrophages in adipose tissue are known to secrete pro-
inflammatory cytokines like tumour necrosis factor (TNF)-a which
have been shown to alter the function of mature adipocytes and the
differentiation of preadipocytes in animal models and cell culture
systems [6,7]. It is thought that due to reduced adipogenesis the
storage capacity of inflamed adipose tissue is reduced resulting in
ectopic lipid accumulation in liver and skeletal muscle leading to
insulin resistance of these metabolically important tissues and
eventually type 2 diabetes [8,9]. However, in human subjects
treatment withthe TNF-a antibody adalimumab [10] or the soluble
TNF-a receptor etanercept [11] did not significantly improve
insulin sensitivity suggesting that in humans macrophages might
affect adipose tissue by different bioactive molecules.
In a recent report from our group we identified the secreted
glycopeptide wingless-type MMTV integration site family member (wnt)-
5a as a potent inhibitor of adipogenesis in human mesenchymal
stem cells [12]. Furthermore, we found that adipose tissue
macrophages of obese and type 2 diabetic human subjects express
wnt5a in vivo and that wnt5a secreted by macrophages inhibits
differentiation of preadipocytes [13]. These recent findings suggest
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in low grade inflammation of adipose tissue in obese humans.
The soluble frizzled related protein (sFRP)-5 is a known inhibitor of
wnt5a signalling [14]. Recently it has been shown in mice that
healthy adipocytes are able to secrete sFRP5 to protect themselves
from wnt5a. In diet induced obesity, sFRP5 expression in adipose
tissue was found to be up-regulated in animal models [14,15].
However, this effect might only be transient, since Ouchi et al.
found sFRP5 levels to fall below control levels under conditions of
severe metabolic dysfunction in relation to obesity [14]. Further-
more, it has been shown in animal models that sFRP5 expression
in adipose tissue is altered by nutritional intervention [15].
Until now data on wnt5a and sFRP5 in human subjects with
obesityarelimited.Sincebothbioactivemoleculescanbedetectedin
blood samplesbyELISAweaimed toaddresstwomajorquestionsin
the present clinical study: (1) are wnt5a serum concentrations
increased in blood samples of human subjects with severe obesity
compared to lean controls and (2) does caloric restriction either
reduce wnt5a and/or improve sFRP5 serum levels which would
suggest a beneficial effect on low grade inflammation in obesity.
Materials and Methods
Study populations
Adipose tissue biopsy study population. The study was
approved by the ethics committee of the University of Cologne and
written informed consent was obtained from all participants.
Subcutaneous adipose tissue biopsies were taken during elective
surgical procedures from n=5 lean subjects (age: 52,464,74, 60%
males, mean BMI 24,0 kg/m
2). Exclusion criteria were: acute or
chronic infectious or immunological disease, cancer, elevation of
liver function tests .3-fold of normal range, serum-creatinin levels
.1.5 mg/dl, hyper- and hypocortisolism, hyper- or hypothyroidism
and lipodystrophy.
Nutritional intervention study population. The study was
approved by the ethics committee of the University of Cologne.
Written informed consent was obtained from each subject before
inclusion into the study. A total number of n=12 metabolically
healthy control subjects were included.Theobesitytreatmentgroup
consisted of n=23 human subjects. As shown in table 1, the groups
were equally distributed regarding age and gender while body
weight and body mass index (BMI) were significantly different.
Inclusion criteria were: age between 20 and 65 years and caucasian
descent. Exclusion criteria were: acute or chronic infections,
presence of cancer, elevations of liver function tests .3-fold of
normal range, serum-creatinin levels .1.5 mg/dl, pregnancy,
untreated hypo- and hyperthyroidism, hypo- and hypercortisolism
and growth hormone deficiency. In the obesity group 2 patients
were smokers, 2 patients were suffering from type 2 diabetes which
was sufficiently controlled only by metformin therapy (metformin
was discontinued during VLCD), 7 patients had hypertension, 4
patients had hyperlipidemia, 1 subject had sleep apnoea syndrome,
1 patient had gastroesophageal reflux disease, 2 patients had
recurrent phlebothrombosis in the past, 7 patients had
hypothyreoidism which was controlled by thyroxine treatment, 2
patients had allergic asthma, 1 patient had history of acute hepatitis
A. None of the control subjects were taking pharmacotherapy for
any kind of diseases. In terms of the obesity group, 7 patients were
taking thyroxine, 2 patient were taking ACE-inhibtors, 5 patients
were taking AT1-blockers, 1 patient was taking a renin inhibitor, 4
patients were on diuretics, 2 patients were taking beta-blockers, 1
patient was taking a Ca
2+ channel blocker, 2 patients were on
phenprocoumon, 2 patients were taking acetylsalicylic acid, 2
patients were taking inhalative beta-sympathomimetics, 2 patients
were taking inhalative steroids, 2 patients were on metformin
therapy which was discontinued during VLCD, 2 patients were
taking anti-depressant agents, 1 patient was taking an antacid and 2
female patients were taking hormonal contraception.
Immunohistology
Human adipose tissue biopsies were fixed in 4% paraformaldehyd/
phosphate-buffered saline solution for 24 h at 4uC. Samples were
dehydrated by ascending ethanol series and embedded in paraffin.
Paraffin sections of 4 mm thicknesswere assembledand driedon tissue
slides. Deparaffinisation was achieved by xylene and 100% ethanol
following rehydration by descending ethanol series.During hydration,
a 5 minute blocking for endogenous peroxidase was done with 0.3%
H2O2 in 95% ethanol. Rehydrated samples were washed with
phosphate-buffered saline containing 0.2% TWEENH 20. Prior to
over-night incubation with sFRP5 antibody (HPA019840; Sigma
Aldrich) at 4uC, an antigen retrieval was performed using sodium
citrate buffer (pH6). Subsequently, samples were washed 265m i ni n
phosphate-buffered saline containing 0.2% TWEENH 20 and
incubated with a second horseradish peroxidase-conjugated antibody
(DAKO EnVision+ System-HRP Labelled Polymer Anti-Rabbit;
DAKO) for 30 min at room temperature (RT). Positive cells were
detected by applying DAKO AEC Substrate Chromogen (DAKO)
for approximately 15 min at RT. Nuclear staining was done using
haemotoxylin (Mayer’s Haemalaun-Solution; AppliChem GmbH).
T i s s u es l i d e sw e r et h e nc o a t e dw i t hg e l atine (Kaiser’s glycerol gelatine;
M e r c kK G a A )a n da n a l y s e db ym i c r o s c o p y .
Nutritional intervention
Formula diet was obtained from Nestle Nutrition (Optifast).
Total caloric intake was approximately 800 kcal/d divided into 4–
5 meals/d. Formula diet was embedded into a commercial
multimodal obesity program which also included nutritional
education, behavioural advice and exercise courses (Optifast-
52 program, www.optifast.de).
Body composition analysis
Body composition was measured by impedance analysis using
the Tanita Body composition analyser BC-418 MA.
Biochemical analysis
Blood samples were taken after an overnight fast at 0, 4 and 12
weeks. The following ELISA for adipokine and wnt-signalling
molecules were used: Leptin: IBL international, order number
Table 1. Baseline characteristics of the control and the
obesity study group.
lean obese p-value
gender (% female) 66.7 65.2 p=0.934
age (years) 37.863.2 42.862.6 p=0.242
weight (kg) 66.562.8 131.964.0 p,0.001
BMI (kg/m
2)2 2 . 3 60.4 44.161.1 p,0.001
fasting insulin (mU/ml) 10.062.2 17.261.9 p,0.01
fasting glucose (mg/dl) 81.964.3 92.763.8 p,0.05
fasting triglycerides (mg/dl) 109.4611.7 146.9611.8 p,0.05
C reactive protein (mg/l) 2.161.4 7.261.0 p,0.01
HOMA-IR index 1.960.3 3.960.6 p,0.01
doi:10.1371/journal.pone.0032437.t001
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national, order number: BV51001 (analytical-sensitivity: 0.2 mg/ml),
wnt5a: Uscn Life Science Inc., order number E83549Hu, (analytical-
sensitivity: 0.051 ng/ml), sFRP5: (analytical-sensitivity:0.64 ng/ml)
Uscn Life Science Inc., order number E92842Hu (analytical-
sensitivity:0.64 ng/ml). The ELISAs were performed according to
the instructions of the manufacturer. According to the manufacturer,
both the wnt5a ELISA and the sFRP5 ELISA had excellent
specificity for detection of human wnt5A and sFRP5 and no
significant cross-reactivity or interference with analogues was
observed. The specificity of the antibodies was confirmed by western
blot experiments. For the wnt5a antibody, two cell line lysates were
tested. The positive one were Hela cells and the negative one were
HEK293. For the sFRP5 antibody, tissue homogenates from human
pancreas and liver tissue were tested separately (personal communi-
cations with the supplying company).
Statistical analysis
Statistical analysis was performed using student’s t-test. p,0.05
was considered to be significant. Data are given as means 6 SEM.
*p ,0.05, ** p,0.01, *** p,0.001.
Figure 1. sFRP5 expression in human adipose tissue. Immunohis-
tochemistry for sFRP5 and hematoxylin staining of human subcutaneous
adipose tissue biopsies. One representative example of n=5 lean control
subjects. Left panel: haematoxylin staining, right panel: immunohistochem-
istry for sFRP5. The reddish colour represents a positive result for expression.
doi:10.1371/journal.pone.0032437.g001
Figure 2. wnt5a and sFRP5 serum concentrations in lean
control subjects and patients with obesity. Serum samples were
taken after an overnight fast and wnt5a and sFRP5 serum concentra-
tions were measured by ELISA. Shown are means6SEM for n=12 lean
control subjects and n=23 patients with obesity. In order to test for
statistical significance, student’s t-test was used, ns=not significant.
doi:10.1371/journal.pone.0032437.g002
wnt5a and sFRP5 in Human Obesity
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sFRP-5 is expressed in mature adipocytes in human
subjects in vivo
In a recent report we have shown that wnt5a is expressed in
adipose tissue macrophages in humans [13]. However, data on
sFRP5 expression in humans to the best of our knowledge have been
shown only on RNA level in whole adipose tissue biopsies, which
contain all types of different cells present in adipose tissue, such as
mature adipocytes, preadipocytes, macrophages, endothelial cells,
lymphocytes etc. In order to examine if mature adipocytes express
sFRP5 in adipose tissue in humans, we first performed immunohis-
tochemistry for sFRP5 in subcutaneous fat biopsies of lean human
controlsubjects.Asshowninfig.1,theseexperimentsclearlyrevealed
that sFRP5 is expressed in the cytoplasm of mature adipocytes.
wnt5a serum concentrations are increased in obese
human subjects
We next measured wnt5a and sFRP5 protein concentrations in
serum samples of n=12 lean control subjects and n=23 subjects
with obesity. As shown in table 1, both groups were equally
distributed in terms of age and gender while body weight and BMI
were almost doubled in the obesity group compared to the lean
controlgroup.Obese subjectsexhibiteda HOMA-IR indexabove 2
indicating insulin resistance. Furthermore, C reactive protein levels
(CRP) in the obese group were above the normal range (,5 mg/l)
and were significant higher compared to lean controls indicating
lowgrade inflammatoryactivity(tab.1).wnt5awasnot detectablein
any serum samples of the control group. In obese human subjects,
however, wnt5a was significantly measurable with serum concen-
trations of 0,7760,31 ng/ml (fig. 2). We next measured sFRP5
protein concentrations in the same serum samples. In contrast to
what was found for wnt5a, sFRP5 was detectable in lean
(9,4761,75 ng/ml) and obese subjects (11,0463,15 ng/ml) with
no significant difference between the groups (fig. 2).
Caloric restriction increases sFRP5 serum concentrations
in obese human subjects
Having shown that both, wnt5a and sFRP5 are detectable in
serum samples of obese human subjects we next examined, if these
bioactive peptides can be influenced by caloric restriction.
Therefore we treated the 23 patients of the obesity group with a
Figure 3. Anthropometric measurements before, during (1 month) and after 3 months of caloric restriction: Body composition was
estimated by impedance analysis. Shown are means6SEM of n=23 obese human subjects during a VLCD. Statistical significance was tested by
student’s t-test, ns=not significant.
doi:10.1371/journal.pone.0032437.g003
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treatment resulted in a significant loss of body weight (131.964.0 to
112.363.2 kg, p,0.001) and BMI (44.161.1 to 37.661.0 kg/m
2,
p,0.001). The weight loss was mainly due to loss of fat mass which
was significantly reduced (45.261.5% to 40.161.6%, p,0.05)
while lean body mass was not significantly altered (68.763.4 to
64.062.8 kg, p=0.282) (fig. 3). However, it has to be mentioned
that even after the caloric restriction obese subjects had still a
BMI.35 kg/m
2 and an average body fat content of 40% (fig. 3).
In order to estimate insulin resistance during caloric restriction
we measured HOMA-IR index which exhibited a significant
reduction throughout the treatment period (fig. 4A). We also
measured leptin and adiponectin serum concentrations (tab. 2) and
calculated the leptin-to-adiponectin ratio (LAR). This marker was
recently shown to be a suitable measure of insulin sensitivity with a
close correlation to hyperinsulinemic euglycemic clamp data [16].
As shown in figure 4B, LAR significantly decreased from 10.761.0
to 3.960.7 (p,0.001) indicating improvement of insulin sensitivity
due to weight loss by caloric restriction. CRP levels were not
significantly altered during the VLCD (before: 7.261.0 mg/l, after
6,761.8 mg/l (p=0.424)). Wnt5a and sFRP5 serum samples were
measured before, during (1 month) and after 3 month of VLCD. As
shown intable 2,weight loss andimproved insulinsensitivitydidnot
result in a significant change in wnt5a serum concentrations. The
wnt5a inhibitor sFRP5, however, was significantly increased by
approximately 70% already after 4 weeks of VLCD. This increase
was sustained to the same extent till the end of the study period
(fig. 4C). Finally we compared wnt5a and sFRP5 values between
subjects with weight loss .15% (n=10) and subjects with weight
loss ,15% (n=13) and found no significant difference (p=0.245
for wnt5a and p=0.342 for sFRP5).
Discussion
In the year 2000 the first report on wnt signalling being important
in the molecular regulation of adipogenesis has been published [17].
Wnt’s are secreted glycopeptides that can act in an autocrine or
paracrine manner. Upon binding to specific receptors wnt molecules
can activate different intracellular pathways which are referred to as
‘‘canonical’’ and ‘‘non-canonical’’ signalling. Activation of both
pathways results mainly in changes of gene expression in target cells
(for review see [18]). Wnt signalling can also be specifically inhibited
by several biochemical mechanisms. Soluble frizzeld-related proteins
(sFRP) can bind to wnt molecules and thereby sequester them from
their cell surface receptors [19]. The soluble factor Dickkopf (DKK)-1
also acts extracellularly by binding to the LRP co-receptor resulting
in a specific inhibition of the canonical pathway [20]. Besides that,
wnt signalling can also be inhibited within the cell either in the
cytoplasm [21] or in the nucleus [22].
Several members of the wnt family have been shown to inhibit
differentiation of mesenchymal precursor cells into mature
adipocytes in cell culture [23], animal models [24] and humans
[25]. For example, wnt5a inhibits adipogenesis of human
mesenchymal stem cells ex vivo by activating the JNK dependent
non-canonical pathway [12]. In agreement it has been shown in an
animal model, that alterations in the locus of the wnt5a, the JNK1
and the PKC-delta gene are associated with obesity, suggesting that
wnt5a acts as an important anti-adipogenic factor not only in cell
culture systems but also in a whole body organism [26].
Figure 4. (A+B) Insulin resistance before, during (1 month) and
after 3 month of caloric restriction: In the present study insulin
resistance was measured by the HOMA-IR index (A) and the
leptin-to-adiponectin ration (LAR) (B) since the later parameter
has been shown to be closely correlated to measures of insulin
resistance by hyperinsulinemic euglycemic clamp experiments
[16]. Data are given as means6SEM of n=23 obese human subjects
during a VLCD. Significance was tested by student’s t-test. (C) sFRP serum
concentrations before, during (1 month) and after 3 months of caloric
restriction: sFRP5 serum concentrations were determined before (0
month), during (1 month) and after (3 months) of a VLCD. In this figure
the levels are shown as fold increase compared to 0 month. The raw data
are given in table 2. Shown are means6SEM of n=23 obese human
subjects during a VLCD. t-test was used to test for statistical significance.
doi:10.1371/journal.pone.0032437.g004
wnt5a and sFRP5 in Human Obesity
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the regulation of adipogenesis, wnt5a and its inhibitor sFRP5 are
particularly important since they both have recently been
implicated in low grade inflammation of adipose tissue. Our
own group found wnt5a to be expressed in adipose tissue
macrophages in human subjects with obesity and type 2 diabetes
in vivo [13]. Moreover, wnt5a secreted from these inflammatory
cells was shown to inhibit differentiation of preadipocytes into
mature fat cells, suggesting wnt5a to act as a pro-inflammatory
factor inhibiting hyperplasia of adipose tissue [13]. Interestingly, in
a recent report of an independent group the wnt5a inhibitor
sFRP5 was identified as an anti-inflammatory factor secreted by
adipocytes of lean animals [14]. In the same study two
independent mouse models of obesity exhibited reduced sFRP5
expressions and an increased wnt5a/sFRP5 ratio in adipose tissue
[14] suggesting these two bioactive molecules to be involved in the
development of obesity and type 2 diabetes. Together, these
findings fit nicely in the concept of the ‘‘overflow-hypothesis’’, in
which a reduced storage capacity of adipose tissue due to limited
expansion leads to ectopic lipid accumulation in liver and skeletal
muscle which is crucial in inducing insulin resistance [8,9]. Since
in humans, sFRP5 has been shown to be expressed on RNA level
in whole adipose tissue biopsies but not in individual mature
adipocytes we performed immunohistology of subcutaneous fat
biopsies in the present study in order to examine in which type of
cells sFRP5 is expressed. These experiments revealed that sFRP5
is indeed expressed in the cytoplasm of mature adipocytes in
humans in vivo (fig. 1).
As mentioned above, wnt signalling normally occurs in an
autocrine or paracrine manner in different tissues and no major
endocrine function has been reported so far. However, in sepsis
wnt5a was shown to be detectable in serum samples of affected
subjects, suggesting that under special circumstances wnt5a might
be released by inflamed tissues into the circulation [27].
Inflammation associated with obesity is by far of a lower grade
compared to the condition of sepsis, however, especially in severe
obese individuals the amount of adipose tissue as a potential source
of wnt5a is extremely increased. Therefore we aimed to investigate
if wnt5a becomes detectable in serum samples in such individuals.
As a control group in our study we included 12 normal weight
individuals of same age and gender distribution. As expected, in
none of these lean control individuals wnt5a was detectable,
confirming that it preferentially acts as an autocrine and/or
paracrine factor but not as an endocrine signalling molecule. In
patients with severe obesity, however, wnt5a was detectable in
serum samples in the absence of any acute or chronic classical
inflammatory or immune disease, which might suggest that wnt5a
can be released from inflamed adipose tissue into systemic
circulation. In contrast to wnt5a, sFRP5 serum concentrations
were detectable in the lean control group as well as in the group of
severe obese subjects. The serum concentrations measured were
not significant different between both groups. However, it has to
be taken into account that the mean body weight of the obese
patients group in the present study was almost doubled compared
to the lean control group with most of the difference account to
increase in adipose tissue mass (fig. 3). Taking this into
consideration, it can be speculated that the amount of sFRP5
released per fat cell is reduced in obese human individuals.
In the present study we also examined the effect of caloric
restriction on wnt5a and sFRP5 serum concentrations in obese
human subjects. Within the three months of the study period,
wnt5a levels were not significantly reduced by caloric restriction
despite a significant weight loss and improved insulin sensitivity
(tab. 2). In contrast to pro-inflammatory wnt5a, serum concen-
trations of anti-inflammatory sFRP5 exhibited a fast response to
caloric restriction. Already after 4 weeks sFRP5 levels were
significantly increased (fig. 4C). Together, these findings suggest
that sFRP5 is more sensitive to nutritional therapy compared to
wnt5a which might have clinical implications, e. g. the use of these
bioactive molecules as biomarkers for anti-inflammatory effects of
dietary interventions.
In summary, the results of the present study together with the
recent reports in humans and mice on wnt signalling in adipose
tissue suggest an interplay of pro-inflammatory wnt5a released
from macrophages and anti-inflammatory sFRP5 secreted by
adipocytes in obese human subjects. These findings might be of
clinical relevance in the future since sFRP5 can be beneficially
influenced by nutritional therapies, as shown in this interventional
study.
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